Cargando…
Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study)
INTRODUCTION: It is unknown if a temporary break in long-term immune-suppressive treatment after vaccination against COVID-19 improves vaccine response. The objective of this study was to evaluate if a 2-week interruption in low-dose weekly methotrexate treatment after SARS-CoV-2 vaccine boosters en...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066090/ https://www.ncbi.nlm.nih.gov/pubmed/35504634 http://dx.doi.org/10.1136/bmjopen-2022-062599 |
_version_ | 1784699730232606720 |
---|---|
author | Abhishek, Abhishek Boyton, RJ McKnight, Áine Coates, Laura Bluett, James Barber, Vicki S Cureton, Lucy Francis, Anne Appelbe, Duncan Eldridge, Lucy Julier, Patrick Peckham, Nicholas Valdes, Ana M Rombach, Ines Altmann, Daniel M Nguyen-Van-Tam, Jonathan Williams, Hywel C Cook, Jonathan Alistair |
author_facet | Abhishek, Abhishek Boyton, RJ McKnight, Áine Coates, Laura Bluett, James Barber, Vicki S Cureton, Lucy Francis, Anne Appelbe, Duncan Eldridge, Lucy Julier, Patrick Peckham, Nicholas Valdes, Ana M Rombach, Ines Altmann, Daniel M Nguyen-Van-Tam, Jonathan Williams, Hywel C Cook, Jonathan Alistair |
author_sort | Abhishek, Abhishek |
collection | PubMed |
description | INTRODUCTION: It is unknown if a temporary break in long-term immune-suppressive treatment after vaccination against COVID-19 improves vaccine response. The objective of this study was to evaluate if a 2-week interruption in low-dose weekly methotrexate treatment after SARS-CoV-2 vaccine boosters enhances the immune response compared with continuing treatment in adults with autoimmune inflammatory conditions. METHODS AND ANALYSIS: An open-label, pragmatic, prospective, parallel group, randomised controlled superiority trial with internal feasibility assessment and nested mechanistic substudy will be conducted in rheumatology and dermatology clinics in approximately 25 UK hospitals. The sample size is 560, randomised 1:1 to intervention and usual care arms. The main outcome measure is anti-spike receptor-binding domain (RBD) antibody level, collected at prebooster (baseline), 4 weeks (primary outcome) and 12 weeks (secondary outcome) post booster vaccination. Other secondary outcome measures are patient global assessments of disease activity, disease flares and their treatment, EuroQol 5- dimention 5-level (EQ-5D-5L), self-reported adherence with advice to interrupt or continue methotrexate, neutralising antibody titre against SARS-CoV-2 (mechanistic substudy) and oral methotrexate biochemical adherence (mechanistic substudy). Analysis of B-cell memory and T-cell responses at baseline and weeks 4 and 12 will be investigated subject to obtaining additional funding. The principal analysis will be performed on the groups as randomised (ie, intention to treat). The difference between the study arms in anti-spike RBD antibody level will be estimated using mixed effects model, allowing for repeated measures clustered within participants. The models will be adjusted for randomisation factors and prior SARS-CoV-2 infection status. ETHICS AND DISSEMINATION: This study was approved by the Leeds West Research Ethics Committee and Health Research Authority (REC reference: 21/HRA/3483, IRAS 303827). Participants will be required to give written informed consent before taking part in the trial. Dissemination will be via peer review publications, newsletters and conferences. Results will be communicated to policymakers. TRIAL REGISTRATION NUMBER: ISRCTN11442263. |
format | Online Article Text |
id | pubmed-9066090 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-90660902022-05-06 Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study) Abhishek, Abhishek Boyton, RJ McKnight, Áine Coates, Laura Bluett, James Barber, Vicki S Cureton, Lucy Francis, Anne Appelbe, Duncan Eldridge, Lucy Julier, Patrick Peckham, Nicholas Valdes, Ana M Rombach, Ines Altmann, Daniel M Nguyen-Van-Tam, Jonathan Williams, Hywel C Cook, Jonathan Alistair BMJ Open Rheumatology INTRODUCTION: It is unknown if a temporary break in long-term immune-suppressive treatment after vaccination against COVID-19 improves vaccine response. The objective of this study was to evaluate if a 2-week interruption in low-dose weekly methotrexate treatment after SARS-CoV-2 vaccine boosters enhances the immune response compared with continuing treatment in adults with autoimmune inflammatory conditions. METHODS AND ANALYSIS: An open-label, pragmatic, prospective, parallel group, randomised controlled superiority trial with internal feasibility assessment and nested mechanistic substudy will be conducted in rheumatology and dermatology clinics in approximately 25 UK hospitals. The sample size is 560, randomised 1:1 to intervention and usual care arms. The main outcome measure is anti-spike receptor-binding domain (RBD) antibody level, collected at prebooster (baseline), 4 weeks (primary outcome) and 12 weeks (secondary outcome) post booster vaccination. Other secondary outcome measures are patient global assessments of disease activity, disease flares and their treatment, EuroQol 5- dimention 5-level (EQ-5D-5L), self-reported adherence with advice to interrupt or continue methotrexate, neutralising antibody titre against SARS-CoV-2 (mechanistic substudy) and oral methotrexate biochemical adherence (mechanistic substudy). Analysis of B-cell memory and T-cell responses at baseline and weeks 4 and 12 will be investigated subject to obtaining additional funding. The principal analysis will be performed on the groups as randomised (ie, intention to treat). The difference between the study arms in anti-spike RBD antibody level will be estimated using mixed effects model, allowing for repeated measures clustered within participants. The models will be adjusted for randomisation factors and prior SARS-CoV-2 infection status. ETHICS AND DISSEMINATION: This study was approved by the Leeds West Research Ethics Committee and Health Research Authority (REC reference: 21/HRA/3483, IRAS 303827). Participants will be required to give written informed consent before taking part in the trial. Dissemination will be via peer review publications, newsletters and conferences. Results will be communicated to policymakers. TRIAL REGISTRATION NUMBER: ISRCTN11442263. BMJ Publishing Group 2022-05-03 /pmc/articles/PMC9066090/ /pubmed/35504634 http://dx.doi.org/10.1136/bmjopen-2022-062599 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Rheumatology Abhishek, Abhishek Boyton, RJ McKnight, Áine Coates, Laura Bluett, James Barber, Vicki S Cureton, Lucy Francis, Anne Appelbe, Duncan Eldridge, Lucy Julier, Patrick Peckham, Nicholas Valdes, Ana M Rombach, Ines Altmann, Daniel M Nguyen-Van-Tam, Jonathan Williams, Hywel C Cook, Jonathan Alistair Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study) |
title | Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study) |
title_full | Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study) |
title_fullStr | Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study) |
title_full_unstemmed | Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study) |
title_short | Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study) |
title_sort | effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after sars-cov-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (vaccine response on/off methotrexate (vroom) study) |
topic | Rheumatology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066090/ https://www.ncbi.nlm.nih.gov/pubmed/35504634 http://dx.doi.org/10.1136/bmjopen-2022-062599 |
work_keys_str_mv | AT abhishekabhishek effectsoftemporarilysuspendinglowdosemethotrexatetreatmentfor2weeksaftersarscov2vaccineboosteronvaccineresponseinimmunosuppressedadultswithinflammatoryconditionsprotocolforamulticentrerandomisedcontrolledtrialandnestedmechanisticsubstudyvaccineresponseono AT boytonrj effectsoftemporarilysuspendinglowdosemethotrexatetreatmentfor2weeksaftersarscov2vaccineboosteronvaccineresponseinimmunosuppressedadultswithinflammatoryconditionsprotocolforamulticentrerandomisedcontrolledtrialandnestedmechanisticsubstudyvaccineresponseono AT mcknightaine effectsoftemporarilysuspendinglowdosemethotrexatetreatmentfor2weeksaftersarscov2vaccineboosteronvaccineresponseinimmunosuppressedadultswithinflammatoryconditionsprotocolforamulticentrerandomisedcontrolledtrialandnestedmechanisticsubstudyvaccineresponseono AT coateslaura effectsoftemporarilysuspendinglowdosemethotrexatetreatmentfor2weeksaftersarscov2vaccineboosteronvaccineresponseinimmunosuppressedadultswithinflammatoryconditionsprotocolforamulticentrerandomisedcontrolledtrialandnestedmechanisticsubstudyvaccineresponseono AT bluettjames effectsoftemporarilysuspendinglowdosemethotrexatetreatmentfor2weeksaftersarscov2vaccineboosteronvaccineresponseinimmunosuppressedadultswithinflammatoryconditionsprotocolforamulticentrerandomisedcontrolledtrialandnestedmechanisticsubstudyvaccineresponseono AT barbervickis effectsoftemporarilysuspendinglowdosemethotrexatetreatmentfor2weeksaftersarscov2vaccineboosteronvaccineresponseinimmunosuppressedadultswithinflammatoryconditionsprotocolforamulticentrerandomisedcontrolledtrialandnestedmechanisticsubstudyvaccineresponseono AT curetonlucy effectsoftemporarilysuspendinglowdosemethotrexatetreatmentfor2weeksaftersarscov2vaccineboosteronvaccineresponseinimmunosuppressedadultswithinflammatoryconditionsprotocolforamulticentrerandomisedcontrolledtrialandnestedmechanisticsubstudyvaccineresponseono AT francisanne effectsoftemporarilysuspendinglowdosemethotrexatetreatmentfor2weeksaftersarscov2vaccineboosteronvaccineresponseinimmunosuppressedadultswithinflammatoryconditionsprotocolforamulticentrerandomisedcontrolledtrialandnestedmechanisticsubstudyvaccineresponseono AT appelbeduncan effectsoftemporarilysuspendinglowdosemethotrexatetreatmentfor2weeksaftersarscov2vaccineboosteronvaccineresponseinimmunosuppressedadultswithinflammatoryconditionsprotocolforamulticentrerandomisedcontrolledtrialandnestedmechanisticsubstudyvaccineresponseono AT eldridgelucy effectsoftemporarilysuspendinglowdosemethotrexatetreatmentfor2weeksaftersarscov2vaccineboosteronvaccineresponseinimmunosuppressedadultswithinflammatoryconditionsprotocolforamulticentrerandomisedcontrolledtrialandnestedmechanisticsubstudyvaccineresponseono AT julierpatrick effectsoftemporarilysuspendinglowdosemethotrexatetreatmentfor2weeksaftersarscov2vaccineboosteronvaccineresponseinimmunosuppressedadultswithinflammatoryconditionsprotocolforamulticentrerandomisedcontrolledtrialandnestedmechanisticsubstudyvaccineresponseono AT peckhamnicholas effectsoftemporarilysuspendinglowdosemethotrexatetreatmentfor2weeksaftersarscov2vaccineboosteronvaccineresponseinimmunosuppressedadultswithinflammatoryconditionsprotocolforamulticentrerandomisedcontrolledtrialandnestedmechanisticsubstudyvaccineresponseono AT valdesanam effectsoftemporarilysuspendinglowdosemethotrexatetreatmentfor2weeksaftersarscov2vaccineboosteronvaccineresponseinimmunosuppressedadultswithinflammatoryconditionsprotocolforamulticentrerandomisedcontrolledtrialandnestedmechanisticsubstudyvaccineresponseono AT rombachines effectsoftemporarilysuspendinglowdosemethotrexatetreatmentfor2weeksaftersarscov2vaccineboosteronvaccineresponseinimmunosuppressedadultswithinflammatoryconditionsprotocolforamulticentrerandomisedcontrolledtrialandnestedmechanisticsubstudyvaccineresponseono AT altmanndanielm effectsoftemporarilysuspendinglowdosemethotrexatetreatmentfor2weeksaftersarscov2vaccineboosteronvaccineresponseinimmunosuppressedadultswithinflammatoryconditionsprotocolforamulticentrerandomisedcontrolledtrialandnestedmechanisticsubstudyvaccineresponseono AT nguyenvantamjonathan effectsoftemporarilysuspendinglowdosemethotrexatetreatmentfor2weeksaftersarscov2vaccineboosteronvaccineresponseinimmunosuppressedadultswithinflammatoryconditionsprotocolforamulticentrerandomisedcontrolledtrialandnestedmechanisticsubstudyvaccineresponseono AT williamshywelc effectsoftemporarilysuspendinglowdosemethotrexatetreatmentfor2weeksaftersarscov2vaccineboosteronvaccineresponseinimmunosuppressedadultswithinflammatoryconditionsprotocolforamulticentrerandomisedcontrolledtrialandnestedmechanisticsubstudyvaccineresponseono AT cookjonathanalistair effectsoftemporarilysuspendinglowdosemethotrexatetreatmentfor2weeksaftersarscov2vaccineboosteronvaccineresponseinimmunosuppressedadultswithinflammatoryconditionsprotocolforamulticentrerandomisedcontrolledtrialandnestedmechanisticsubstudyvaccineresponseono |